Keros Therapeutics (KROS) EBIAT (2019 - 2025)
Keros Therapeutics' EBIAT history spans 7 years, with the latest figure at -$23.5 million for Q4 2025.
- For Q4 2025, EBIAT rose 49.03% year-over-year to -$23.5 million; the TTM value through Dec 2025 reached $87.0 million, up 146.44%, while the annual FY2025 figure was $87.0 million, 146.44% up from the prior year.
- EBIAT reached -$23.5 million in Q4 2025 per KROS's latest filing, down from -$7.3 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $148.5 million in Q1 2025 to a low of -$53.0 million in Q3 2024.
- Average EBIAT over 5 years is -$20.8 million, with a median of -$28.5 million recorded in 2022.
- Peak YoY movement for EBIAT: crashed 328.21% in 2022, then surged 444.32% in 2025.
- A 5-year view of EBIAT shows it stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then crashed by 35.42% to -$40.2 million in 2023, then decreased by 14.37% to -$46.0 million in 2024, then surged by 49.03% to -$23.5 million in 2025.
- Per Business Quant, the three most recent readings for KROS's EBIAT are -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025).